UBS maintains buy rating on Max Healthcare with ₹1,550 target
pre-market1 source ↓written by the desknot a recommendation
- firm highlighted
- 21% revenue growth
- in Q2
- 23% EBITDA increase
- and upcoming facilities
- 160-bed Mohali hospital
UBS has reaffirmed its buy rating on Max Healthcare, setting a target price of ₹1,550. The firm highlighted a 21% revenue growth and 23% EBITDA increase in Q2, driven by ongoing brownfield expansions. Key projects include the commissioning of a 160-bed Mohali hospital and upcoming facilities in Nanavati and Smart Hospital, enhancing capacity and growth potential.
Not investment advice. For informational purposes only.